1 / 8

Anti-Infective Pharmaceuticals Market in India 2012

Bharatbook.com introduces a new report on " Anti-Infective Pharmaceuticals Market in India 2012 " it has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices.

Télécharger la présentation

Anti-Infective Pharmaceuticals Market in India 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. I Anti-Infective Pharmaceuticals Market - India September 2011

  2. Executive Summary Anti-infective pharmaceuticals market in India is valued at INR X bn in 20-- Market Market is expected to grow at a CAGR of x% from 20---- Anti infectives are the largest contributor to domestic sales, contributing around y% Drivers: Challenges: Pricing pressureLogistic problems in the vaccine market Increasing patient population Drivers andChallenges Increasing number of vaccine approvalsIncrease in health insurances Introduction of new drugs Phases of clinical trial Drug regulation and patents Approval and licensing of drugsPatents Highly fragmented market with large number of players Major foreign players in the market include Gilead inc, Abbott, Glaxosmithkline etcMajor domestic companies include Ranbaxy, Cipla, Dr. Reddy’s, Sun Pharmaceuticals, PanaceaBiotech, Torrent Pharmaceuticals among others Competition Strategicrecommendations Foray into the adult vaccine marketPartnership with Governmental and private bodies 2 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  3. •Introduction •Market Overview •Drivers & Challenges •Government Initiatives •Drug Regulation and Patents •Competition •Strategic Recommendations 3 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  4. Indian anti-infectives market is expected to witness an enormous growth over the coming years Indian Market - Overview Market Size and Growth •Anti-infectives belong to the acute segment which makes up around z% of the total pharmaceutical INR bn 200 industry x% x6 150 x5 Anti-infectives are the largest contributor to domesticpharmaceuticals sales, contributing around y% x3 x4 100 x1 x2 Cephalosporins, penicillins and quinolones are key drugclasses among anti-infectives, with a share of around z% ofthe country’s anti-infectives market 50 0 • Presently the market has a size of INR X bn, and is expected to grow at a CAGR of x% from 20----- 2010 2011e 2012e 2013e 2014e 2015e Top pharmaceutical segments - 2010 • In 2010 GSK’s Augmentin was the highest selling drug with sales of INR Y bn 0 2 4 6 8 10 12 14 16 18 Zifi, Taxim ,Monocef, Mox, Taxim-O , Zinacef and Gerimacwere the other top selling drugs % anti-infectives CVS y1y2 • India has emerged as one of the leading vaccine manufacturer in recent times, producing z% of the gastro CNS y3y4 respiratory diabetes y5 y6y7 global health vaccines Pentaxim, Varivax and Prevenar were the top sellingvaccines in 20-- painoncology y8 Source: 4 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  5. Drivers & Challenges - Summary Drivers Challenges Increasing patient population Pricing pressure Increasing number of vaccineapprovals Logistic problems in the vaccinemarket Increase in health insurancesIntroduction of new drugs 5 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  6. Government Initiatives - Summary Changes in tax structure Control programmes Government Initiatives PPP Projects Reduction in drug prices 6 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  7. Major domestic players in the market (1/9) Company Snapshot: Company 1 Corporate Information Financial Performance Revenue Revenue ProfitINR bn INR bn Headquarters Location A Profit / Loss r4 60 Founded 19-- 100 r3 r1 r2 40 Products Product 1, product 2 50 20 Key People Person X- MD 0 0 2008 2009 2010 2011 Business Highlights • Employing around XX people, Company 1 is India’s largest pharmaceutical company, having manufacturing facilities inseven countries and serving customers in over YY countries • In June 20--, the company entered into an alliance with Company X to create an innovator and genericpharmaceuticals powerhouse • Company 1 launched anti-infectives such as Product 1 and Product 2 for the first time in India and is trying to promotethe concept of product 3 on a local basis •Signed an agreement with Company X for manufacturing and marketing 3 new HIV/AIDS drugs in India anddeveloping countries • Has been working on an anti-malaria research project since May 20-- to develop cheap anti malarial drugs Source: 7 ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA 2011.PPT

  8. For more details about the report visit: http://www.bharatbook.com/medical-devices-market-research-reports/adonis-medical-systems-pvt-ltd-company-profile-2011.html http://www.bharatbook.com/healthcare-market-research-reports/anti-infective-pharmaceuticals-market-in-india-2012.html Bharat Book Bureau Phone : +91 22 27810772, 27810773 Fax : +91 22 27812290 E-mail : info@bharatbook.com Website : www.bharatbook.com

More Related